Nuvectis Pharma
NVCT
NVCT
48 hedge funds and large institutions have $32M invested in Nuvectis Pharma in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 26 increasing their positions, 8 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
9% less funds holding
Funds holding: 53 → 48 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Holders
48
Holding in Top 10
–
Calls
$1.12M
Puts
$724K
Top Buyers
| 1 | +$1.18M | |
| 2 | +$957K | |
| 3 | +$635K | |
| 4 |
OCM
Occam Crest Management
Darien,
Connecticut
|
+$587K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$282K |
Top Sellers
| 1 | -$258K | |
| 2 | -$196K | |
| 3 | -$171K | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$141K |
| 5 |
Goldman Sachs
New York
|
-$122K |
